Discontinuation report REYATAZ
| Report ID | 280161 |
| Drug Identification Number | 02248611 |
| Brand name | REYATAZ |
| Common or Proper name | Atazanavir sulfate |
| Company Name | BRISTOL-MYERS SQUIBB CANADA |
| Market Status | MARKETED |
| Active Ingredient(s) | ATAZANAVIR |
| Strength(s) | 200MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 1 X 60 |
| Anatomical Therapeutical Chemical (ATC) code | J05AE |
| Anatomical Therapeutical Chemical (ATC) description | DIRECT ACTING ANTIVIRALS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2026-06-30 |
| Actual discontinuation date | |
| Remaining supply date | 2026-06-30 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2344 BOUL. ALFRED-NOBEL, SUITE 300 ST-LAURENT, QUEBEC CANADA H4S 0A4 |
| Company contact information | For more information please contact the Customer Service Desk at 1-800-267-0005 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2026-03-09 | French | Compare |
| v1 | 2026-03-09 | English | Compare |
Showing 1 to 2 of 2